$NKTR
Nektar Therapeutics

2014 Form 10-K Financial Statement

#000119312515063338 Filed on February 26, 2015

View on sec.gov

Income Statement

Concept 2014 2013 Q4 2013 Q3
Revenue $200.7M $31.15M $60.91M
YoY Change 34.77% 47.29% 230.81%
Cost Of Revenue $28.53M $8.960M $12.88M
YoY Change -25.91% 22.91% 78.15%
Gross Profit $172.2M $22.19M $48.03M
YoY Change 55.94% 60.12% 329.47%
Gross Profit Margin 85.78% 71.23% 78.86%
Selling, General & Admin $40.90M $9.800M $10.60M
YoY Change 0.99% -10.09% 4.95%
% of Gross Profit 23.76% 44.17% 22.07%
Research & Development $147.7M $48.25M $43.91M
YoY Change -22.25% 4.04% 29.1%
% of Gross Profit 85.81% 217.47% 91.43%
Depreciation & Amortization $11.70M $3.400M $3.600M
YoY Change -10.0% -12.82% 0.0%
% of Gross Profit 6.8% 15.32% 7.5%
Operating Expenses $147.7M $48.25M $43.91M
YoY Change -22.25% 4.04% 29.1%
Operating Profit -$16.49M -$35.89M -$6.525M
YoY Change -86.28% -17.26% -80.17%
Interest Expense $17.87M -$10.10M $4.587M
YoY Change -3.16% 5.21% -19.48%
% of Operating Profit
Other Income/Expense, Net -$37.94M -$9.825M
YoY Change -4.28% -5.76%
Pretax Income -$54.43M -$46.00M -$16.35M
YoY Change -66.21% -13.21% -62.26%
Income Tax -$512.0K $1.600M $193.0K
% Of Pretax Income
Net Earnings -$53.92M -$47.66M -$16.54M
YoY Change -66.72% -9.95% -62.01%
Net Earnings / Revenue -26.86% -153.02% -27.16%
Basic Earnings Per Share -$0.41 -$0.14
Diluted Earnings Per Share -$424.7K -$0.41 -$0.14
COMMON SHARES
Basic Shares Outstanding 116.1M shares 115.8M shares
Diluted Shares Outstanding 115.8M shares

Balance Sheet

Concept 2014 2013 Q4 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $237.8M $237.0M $183.6M
YoY Change 0.34% -14.5% -42.5%
Cash & Equivalents $12.40M $39.07M $65.41M
Short-Term Investments $225.5M $198.0M $118.1M
Other Short-Term Assets $33.80M $5.175M $4.759M
YoY Change 550.0% -61.27% -32.04%
Inventory $13.00M $13.45M $15.08M
Prepaid Expenses
Receivables $3.600M $2.229M $4.557M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $288.2M $257.9M $207.9M
YoY Change 11.75% -18.04% -40.06%
LONG-TERM ASSETS
Property, Plant & Equipment $70.40M $66.97M $65.08M
YoY Change 5.07% -7.26% -11.16%
Goodwill $76.50M $76.50M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.600M $8.170M $8.510M
YoY Change -80.12% -13.48% -12.52%
Total Long-Term Assets $153.4M $176.6M $175.1M
YoY Change -13.14% -3.56% -9.98%
TOTAL ASSETS
Total Short-Term Assets $288.2M $257.9M $207.9M
Total Long-Term Assets $153.4M $176.6M $175.1M
Total Assets $441.6M $434.5M $383.0M
YoY Change 1.63% -12.71% -29.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.700M $9.115M $3.723M
YoY Change -70.33% 218.37% 41.88%
Accrued Expenses $26.80M $6.243M $10.77M
YoY Change -39.5% -22.04% 66.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.500M
YoY Change
Total Short-Term Liabilities $64.00M $98.22M $80.91M
YoY Change -34.83% 25.06% 16.47%
LONG-TERM LIABILITIES
Long-Term Debt $129.1M $203.0M $134.0M
YoY Change -36.4% 48.61% -49.28%
Other Long-Term Liabilities $212.1M $19.26M $9.217M
YoY Change -4.97% 78.11% -14.08%
Total Long-Term Liabilities $341.2M $19.26M $9.217M
YoY Change -19.94% 78.11% -14.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $64.00M $98.22M $80.91M
Total Long-Term Liabilities $341.2M $19.26M $9.217M
Total Liabilities $405.3M $524.4M $433.3M
YoY Change -22.71% 16.34% -2.88%
SHAREHOLDERS EQUITY
Retained Earnings -$1.732B -$1.685B
YoY Change 10.32% 11.02%
Common Stock $1.644B $1.636B
YoY Change 1.6% 1.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $36.30M -$89.90M -$50.25M
YoY Change
Total Liabilities & Shareholders Equity $441.6M $434.5M $383.0M
YoY Change 1.63% -12.71% -29.26%

Cashflow Statement

Concept 2014 2013 Q4 2013 Q3
OPERATING ACTIVITIES
Net Income -$53.92M -$47.66M -$16.54M
YoY Change -66.72% -9.95% -62.01%
Depreciation, Depletion And Amortization $11.70M $3.400M $3.600M
YoY Change -10.0% -12.82% 0.0%
Cash From Operating Activities -$142.0M $53.70M -$19.80M
YoY Change 268.57% -213.29% -27.21%
INVESTING ACTIVITIES
Capital Expenditures $9.976M -$2.700M -$600.0K
YoY Change 143.85% -44.9% -76.0%
Acquisitions
YoY Change
Other Investing Activities -$27.60M -$79.40M $42.30M
YoY Change -151.11% -218.33% -1558.62%
Cash From Investing Activities -$37.60M -$82.20M $41.80M
YoY Change -175.34% -232.15% -874.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 153.0M 2.100M 1.900M
YoY Change 6804.33% 950.0% -102.04%
NET CHANGE
Cash From Operating Activities -142.0M 53.70M -19.80M
Cash From Investing Activities -37.60M -82.20M 41.80M
Cash From Financing Activities 153.0M 2.100M 1.900M
Net Change In Cash -26.60M -26.40M 23.90M
YoY Change -295.62% -276.0% -119.0%
FREE CASH FLOW
Cash From Operating Activities -$142.0M $53.70M -$19.80M
Capital Expenditures $9.976M -$2.700M -$600.0K
Free Cash Flow -$152.0M $56.40M -$19.20M
YoY Change 256.6% -232.71% -22.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
131381612 shares
CY2012Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
25000000
CY2012Q3 nktr Convertible Subordinated Notes Repaid
ConvertibleSubordinatedNotesRepaid
172400000
CY2014Q2 dei Entity Public Float
EntityPublicFloat
1625943780
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
197811000
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
13576000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15312000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
47018000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
14067000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25437000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
116494000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
116494000 shares
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
10587000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
586040000
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
125000000
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
82384000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
84148000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
98221000
CY2013Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
8049000
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
6917000
CY2013Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1181000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9115000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1732393000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1643660000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6243000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-89903000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
19256000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
434527000
CY2013Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
23664000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
16363000
CY2013Q4 us-gaap Liabilities
Liabilities
524430000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14254000
CY2013Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3536000
CY2013Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39067000
CY2013Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
6261000
CY2013Q4 us-gaap Goodwill
Goodwill
76501000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
66974000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
197959000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
586190000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
25000000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2539000
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
35588000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
61707000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
25962000
CY2013Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3359000
CY2013Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
2300000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
391385000
CY2013Q4 us-gaap Assets
Assets
434527000
CY2013Q4 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
1000000
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
150000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
150000
CY2013Q4 us-gaap Inventory Net
InventoryNet
13452000
CY2013Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3947000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2229000
CY2013Q4 nktr Liability Related To Sale Of Potential Future Royalties
LiabilityRelatedToSaleOfPotentialFutureRoyalties
128520000
CY2013Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
262026000
CY2013Q4 nktr Cash And Restricted Cash
CashAndRestrictedCash
37614000
CY2014Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
4139000
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
6917000
CY2014Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
13000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
197959000
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5175000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8170000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
257882000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
14685000
CY2013Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6146000
CY2013Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
25000000
CY2013Q4 nktr Depreciable Property Plant And Equipment Gross
DepreciablePropertyPlantAndEquipmentGross
144861000
CY2013Q4 nktr Number Of Customers Accounted For Major Accounts Receivable
NumberOfCustomersAccountedForMajorAccountsReceivable
3 Customer
CY2013Q4 nktr Liability Related To Sale Of Potential Future Royalties Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent
7000000
CY2013Q4 nktr Deferred Tax Assets Capitalized Research Expenses
DeferredTaxAssetsCapitalizedResearchExpenses
17687000
CY2013Q4 nktr Deferred Tax Assets Depreciation Property And Equipment
DeferredTaxAssetsDepreciationPropertyAndEquipment
8580000
CY2013Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2013Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
121520000
CY2013Q4 nktr Refundable Milestone Payment Liabilities
RefundableMilestonePaymentLiabilities
70000000
CY2013Q4 nktr Depreciable Property Plant And Equipment Net
DepreciablePropertyPlantAndEquipmentNet
60713000
CY2013Q4 nktr Letters Of Credit Outstanding
LettersOfCreditOutstanding
2400000
CY2013Q4 nktr Deferred Tax Assets From Sale Of Future Royalties
DeferredTaxAssetsFromSaleOfFutureRoyalties
28057000
CY2013Q4 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
16905000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131216000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131216000 shares
CY2014Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
10.50
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
125000000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5567000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
595690000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
76911000
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
8651000
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
175000
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
4268000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
93807000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
452000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
64047000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1567000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2703000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1786309000
CY2014Q4 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
16900000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
5187000
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
5572000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1824195000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6418000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
36332000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14721000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
25662000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
5344000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
5037000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
441621000
CY2014Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
10015000
CY2014Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
3900000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
24473000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
27522000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4892000
CY2014Q4 us-gaap Liabilities
Liabilities
405289000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5749000
CY2014Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
4512000
CY2014Q4 us-gaap Purchase Obligation
PurchaseObligation
7200000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
4750000
CY2014Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
1364000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12365000
CY2014Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
16309000
CY2014Q4 us-gaap Goodwill
Goodwill
76501000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70368000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
25000000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
225459000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
595866000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
25000000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2218000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
29758000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
66666000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
21948000
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5565000
CY2014Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
2700000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
423776000
CY2014Q4 us-gaap Assets
Assets
441621000
CY2014Q4 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
1200000
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
176000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
176000
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
51900000
CY2014Q4 us-gaap Inventory Net
InventoryNet
12952000
CY2014Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2200000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3607000
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
225459000
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8817000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6552000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
288200000
CY2014Q4 us-gaap Capital Leases Future Minimum Sublease Rentals
CapitalLeasesFutureMinimumSubleaseRentals
4800000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
8288000
CY2014Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5187000
CY2014Q4 nktr Depreciable Property Plant And Equipment Gross
DepreciablePropertyPlantAndEquipmentGross
147866000
CY2014Q4 nktr Number Of Customers Accounted For Major Accounts Receivable
NumberOfCustomersAccountedForMajorAccountsReceivable
3 Customer
CY2014Q4 nktr Restricted Stock Units Outstanding
RestrictedStockUnitsOutstanding
0 shares
CY2014Q4 nktr Debt Capital Lease And Other Long Term Liabilities
DebtCapitalLeaseAndOtherLongTermLiabilities
151800000
CY2014Q4 nktr Deferred Tax Assets Capitalized Research Expenses
DeferredTaxAssetsCapitalizedResearchExpenses
14795000
CY2014Q4 nktr Deferred Tax Assets Depreciation Property And Equipment
DeferredTaxAssetsDepreciationPropertyAndEquipment
8264000
CY2014Q4 nktr Liability Related To Sale Of Potential Future Royalties
LiabilityRelatedToSaleOfPotentialFutureRoyalties
120471000
CY2014Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
262824000
CY2014Q4 nktr Cash And Restricted Cash
CashAndRestrictedCash
26136000
CY2014Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2014Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
120471000
CY2014Q4 nktr Depreciable Property Plant And Equipment Net
DepreciablePropertyPlantAndEquipmentNet
54059000
CY2014Q4 nktr Letters Of Credit Outstanding
LettersOfCreditOutstanding
2400000
CY2014Q4 nktr Number Of Securities Available For Issuance Under Equity Compensation Plans
NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans
2812000 shares
CY2014Q4 nktr Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding
21995000 shares
CY2014Q4 nktr Deferred Tax Assets From Sale Of Future Royalties
DeferredTaxAssetsFromSaleOfFutureRoyalties
20153000
CY2014Q4 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
7708000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
117200000
nktr Partial Repayment Of Royalty Sale Proceeds
PartialRepaymentOfRoyaltySaleProceeds
10000000
nktr Proceeds From Sale Of Potential Future Royalties
ProceedsFromSaleOfPotentialFutureRoyalties
124000000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
54783000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
61254000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.612 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-38527000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y2M12D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009 pure
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
115732000 shares
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.40
CY2013 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
268068000
CY2013 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1014000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1300000
CY2013 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss
-268000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
51800000
CY2013 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8208000
CY2013 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
44846000
CY2013 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2992000
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-824000
CY2013 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-6423000
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-4817000
CY2013 us-gaap Available For Sale Securities Gross Realized Gains Losses Sale Proceeds
AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds
2900000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-120130000
CY2013 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
6273000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-162837000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-39638000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-159768000
CY2013 us-gaap Royalty Revenue
RoyaltyRevenue
1148000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1124000
CY2013 us-gaap Revenues
Revenues
148921000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4091000
CY2013 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-664000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-162013000
CY2013 us-gaap Interest Paid
InterestPaid
17590000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3576000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17708000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-161068000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17708000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
406000
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
32000
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1286000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12399000
CY2013 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
5481000
CY2013 us-gaap Interest Expense
InterestExpense
18453000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
190010000
CY2013 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2013 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
49000
CY2013 us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
-470000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
13630000
CY2013 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-65000
CY2013 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-20000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-55919000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2245000
CY2013 us-gaap Cost Of Goods Sold
CostOfGoodsSold
38509000
CY2013 us-gaap Depreciation
Depreciation
13000000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
14275000
CY2013 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
4100000
CY2013 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-166000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2216000
CY2013 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
8208000
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2013 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1000000
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
7808000
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
271000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1915000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
49909000
CY2013 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1838000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1839000
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
269051000
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
50000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2900000
CY2013 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
1026000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40532000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6199000
CY2013 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
319181000
CY2013 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
2887000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
17708000
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
422000
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
55042000
CY2013 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
9164000
CY2013 nktr Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs
RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts
-3000000
CY2013 nktr Increase Decrease In Milestone Payment Liabilities
IncreaseDecreaseInMilestonePaymentLiabilities
70000000
CY2013 nktr Percentage Of Accounts Receivable Customers Two
PercentageOfAccountsReceivableCustomersTwo
0.28 pure
CY2013 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
80872000
CY2013 nktr Valuation Allowance Related To Stock Based Compensation And Exercises
ValuationAllowanceRelatedToStockBasedCompensationAndExercises
35600000
CY2013 nktr Percentage Of Accounts Receivable Customers Three
PercentageOfAccountsReceivableCustomersThree
0.28 pure
CY2013 nktr Percentage Of Accounts Receivable Customers One
PercentageOfAccountsReceivableCustomersOne
0.30 pure
CY2013 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
22055000
CY2013 nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
-595000
CY2013 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
22309000
CY2013 nktr Property And Equipment Acquired Through Capital Leases And Other Financing
PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing
2000000
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2014 dei Trading Symbol
TradingSymbol
NKTR
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.516 pure
CY2014 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M6D
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-142006000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y2M12D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016 pure
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
126873000 shares
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-500000
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-53916000
CY2014 us-gaap Interest Paid
InterestPaid
17445000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1378000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17017000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-56414000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17017000
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0000906709
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2014 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Reclassifications</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported total revenue, operating loss or net loss or total assets, liabilities or stockholders&#x2019; equity (deficit).</p> </div>
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
116536000
CY2014 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
297251000
CY2014 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
964000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1986000
CY2014 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss
-95000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9700000
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
46984000
CY2014 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
25152000
CY2014 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
3536000
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-386000
CY2014 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3294000
CY2014 us-gaap Available For Sale Securities Gross Realized Gains Losses Sale Proceeds
AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds
21700000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-16485000
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2933000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54302000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-37943000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-54428000
CY2014 us-gaap Royalty Revenue
RoyaltyRevenue
329000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
814000
CY2014 us-gaap Revenues
Revenues
200707000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9976000
CY2014 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
560000
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-31000
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-109000
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-487000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4664000
CY2014 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-8505000
CY2014 us-gaap Interest Expense
InterestExpense
17869000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
147734000
CY2014 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2014 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-26702000
CY2014 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-31000
CY2014 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-17000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-19050000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-512000
CY2014 us-gaap Cost Of Goods Sold
CostOfGoodsSold
28533000
CY2014 us-gaap Depreciation
Depreciation
11700000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
12927000
CY2014 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
3400000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
152984000
CY2014 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
46984000
CY2014 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
617000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2014 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
7311000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2832000
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
217192000
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3200000
CY2014 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
291000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40925000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
273000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-37571000
CY2014 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-482000
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-481000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6359000
CY2014 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
247995000
CY2014 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
21661000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
17017000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
11831000
CY2014 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-13801000
CY2014 nktr Partial Repayment Of Royalty Sale Proceeds
PartialRepaymentOfRoyaltySaleProceeds
7000000
CY2014 nktr Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs
RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts
-7000000
CY2014 nktr Number Of Operating Business Segment
NumberOfOperatingBusinessSegment
1 Segment
CY2014 nktr Sublease Term Commenced End Date
SubleaseTermCommencedEndDate
January 31, 2020
CY2014 nktr Increase Decrease In Milestone Payment Liabilities
IncreaseDecreaseInMilestonePaymentLiabilities
-70000000
CY2014 nktr Percentage Of Accounts Receivable Customers Two
PercentageOfAccountsReceivableCustomersTwo
0.31 pure
CY2014 nktr Percentage Ceiling On Rent Increase
PercentageCeilingOnRentIncrease
0.03 pure
CY2014 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
153289000
CY2014 nktr Percentage Of Amount Realized Upon Ultimate Settlement
PercentageOfAmountRealizedUponUltimateSettlement
0.50 pure
CY2014 nktr Valuation Allowance Related To Stock Based Compensation And Exercises
ValuationAllowanceRelatedToStockBasedCompensationAndExercises
35600000
CY2014 nktr Federal Orphan Drug Credits Expiration Year
FederalOrphanDrugCreditsExpirationYear
2026
CY2014 nktr Royalty Agreement Contingent Payment Description
RoyaltyAgreementContingentPaymentDescription
As a result of worldwide net sales of MIRCERA for the 12 month periods ended on December 31, 2013 and 2012 not reaching certain minimum thresholds.
CY2014 nktr Percentage Of Accounts Receivable Customers Three
PercentageOfAccountsReceivableCustomersThree
0.15 pure
CY2014 nktr Number Of Components Within Business Segment
NumberOfComponentsWithinBusinessSegment
2 Segment
CY2014 nktr Federal Orphan Drug Credits
FederalOrphanDrugCredits
17700000
CY2014 nktr Maturity Term Of Investments In Marketable Securities To Be Considered As Cash Equivalents
MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents
Three months
CY2014 nktr Redemption Price As Percentage Of Principal Amount In Case Of Change Of Control
RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl
1.01 pure
CY2014 nktr Cash Severance Payment For To Chief Executive Officer
CashSeverancePaymentForToChiefExecutiveOfficer
24 months base salary plus annual target incentive pay
CY2014 nktr Maximum Contribution Per Employee Annual Salary Percentage
MaximumContributionPerEmployeeAnnualSalaryPercentage
0.60 pure
CY2014 nktr Maturity Term Of Investments Considered As Short Term
MaturityTermOfInvestmentsConsideredAsShortTerm
Less than one year
CY2014 nktr Redemption Price As Percentage Of Principal Amount In Case Of Sale Of Assets
RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets
1.00 pure
CY2014 nktr Severance Payment Period For Employees
SeverancePaymentPeriodForEmployees
6 months
CY2014 nktr Estimated Annual Interest Rate On Royalty Liability
EstimatedAnnualInterestRateOnRoyaltyLiability
0.17 pure
CY2014 nktr Debt Instrument Maximum Maturity Period
DebtInstrumentMaximumMaturityPeriod
Two years or less
CY2014 nktr Potential Development Milestones
PotentialDevelopmentMilestones
130300000
CY2014 nktr Sublease Term Commenced Period
SubleaseTermCommencedPeriod
114 months
CY2014 nktr Sublease Term Commenced Start Date
SubleaseTermCommencedStartDate
August 2010
CY2014 nktr Debt Instrument Weighted Average Maturity Period One
DebtInstrumentWeightedAverageMaturityPeriodOne
One year or less
CY2014 nktr Capital Leases Termination Date
CapitalLeasesTerminationDate
2016-10-05
CY2014 nktr Severance Payment Period For Executives
SeverancePaymentPeriodForExecutives
12 months
CY2014 nktr Unrecognized Tax Benefits Period Increase Decrease Reasonable Period Of Change
UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange
Next twelve months
CY2014 nktr Percentage Of Accounts Receivable Customers One
PercentageOfAccountsReceivableCustomersOne
0.40 pure
CY2014 nktr Research And Development Expenditure Credits
ResearchAndDevelopmentExpenditureCredits
4700000
CY2014 nktr Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
116536000
CY2014 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
21937000
CY2014 nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
-9197000
CY2014 nktr Convertible Subordinated Notes Maturity Date
ConvertibleSubordinatedNotesMaturityDate
2012-09-28
CY2014 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
20888000
CY2014 nktr Number Of Reporting Units To Evaluate Goodwill For Impairment
NumberOfReportingUnitsToEvaluateGoodwillForImpairment
1 Reporting_Unit
CY2014 nktr Property And Equipment Acquired Through Capital Leases And Other Financing
PropertyAndEquipmentAcquiredThroughCapitalLeasesAndOtherFinancing
5231000
CY2014 nktr Equipment Purchase Obligation Payable Term
EquipmentPurchaseObligationPayableTerm
P3Y
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.622 pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-129756000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
114820000 shares
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.50
CY2012 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
164662000
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
25000000
CY2012 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1021000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
2809000
CY2012 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss
1206000
CY2012 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4117000
CY2012 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
35399000
CY2012 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2437000
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
746000
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-6031000
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5613000
CY2012 us-gaap Available For Sale Securities Gross Realized Gains Losses Sale Proceeds
AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds
5400000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-141201000
CY2012 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
591000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-171109000
CY2012 us-gaap Repayments Of Subordinated Debt
RepaymentsOfSubordinatedDebt
172407000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30248000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-171449000
CY2012 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
42548000
CY2012 us-gaap Royalty Revenue
RoyaltyRevenue
4874000
CY2012 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
4500000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3298000
CY2012 us-gaap Revenues
Revenues
81191000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10583000
CY2012 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2520000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-171855000
CY2012 us-gaap Interest Paid
InterestPaid
9620000
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
867000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16199000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-174258000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16199000
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-487000
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
60000
CY2012 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
864000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9384000
CY2012 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4034000
CY2012 us-gaap Interest Expense
InterestExpense
15489000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
148675000
CY2012 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2012 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-49000
CY2012 us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
470000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10125000
CY2012 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-16000
CY2012 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-227000
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-60007000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
406000
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-137000
CY2012 us-gaap Cost Of Goods Sold
CostOfGoodsSold
30428000
CY2012 us-gaap Depreciation
Depreciation
13800000
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
14508000
CY2012 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
2900000
CY2012 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
5278000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
26801000
CY2012 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
4117000
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
6320000
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
236000
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1495000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
113020000
CY2012 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1029000
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
893000
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
222392000
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-48000
CY2012 us-gaap Income Tax Reconciliation Tax Settlements Foreign
IncomeTaxReconciliationTaxSettlementsForeign
6510000
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2800000
CY2012 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
-10000
CY2012 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
77940000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41614000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-122000
CY2012 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
307887000
CY2012 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5378000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
16199000
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-422000
CY2012 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1675000
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
47349000
CY2012 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
3275000
CY2012 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
137000
CY2012 nktr Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs
RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts
119588000
CY2012 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
30127000
CY2012 nktr Payment For Transaction Costs
PaymentForTransactionCosts
4400000
CY2012 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
10791000
CY2012 nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
5547000
CY2012 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
18057000
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2013Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
11810000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-45106000
CY2013Q1 us-gaap Revenues
Revenues
23004000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-55063000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45618000
CY2013Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
11661000
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2014Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
5795000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36402000
CY2014Q1 us-gaap Revenues
Revenues
19771000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-46201000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38338000
CY2014Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7907000
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2013Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
10324000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-32605000
CY2013Q2 us-gaap Revenues
Revenues
33862000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-42748000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52230000
CY2013Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5011000
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2014Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
5802000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22916000
CY2014Q2 us-gaap Revenues
Revenues
28513000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-32637000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36702000
CY2014Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5108000
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
14672000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6525000
CY2013Q3 us-gaap Revenues
Revenues
60909000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-16543000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43914000
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
12877000
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.53
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.55
CY2014Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
6096000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
80321000
CY2014Q3 us-gaap Revenues
Revenues
132871000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
70605000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34200000
CY2014Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
9220000
CY2013Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2013Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2013Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
8040000
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-35894000
CY2013Q4 us-gaap Revenues
Revenues
31146000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-47659000
CY2013Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48248000
CY2013Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8960000
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2014Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
7460000
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-37488000
CY2014Q4 us-gaap Revenues
Revenues
19551000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-45683000
CY2014Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38494000
CY2014Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6298000

Files In Submission

Name View Source Status
0001193125-15-063338-index-headers.html Edgar Link pending
0001193125-15-063338-index.html Edgar Link pending
0001193125-15-063338.txt Edgar Link pending
0001193125-15-063338-xbrl.zip Edgar Link pending
d842626d10k.htm Edgar Link pending
d842626dex1016.htm Edgar Link pending
d842626dex211.htm Edgar Link pending
d842626dex231.htm Edgar Link pending
d842626dex311.htm Edgar Link pending
d842626dex312.htm Edgar Link pending
d842626dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g842626g16f09.jpg Edgar Link pending
g842626st99.jpg Edgar Link pending
nktr-20141231.xml Edgar Link completed
nktr-20141231.xsd Edgar Link pending
nktr-20141231_cal.xml Edgar Link unprocessable
nktr-20141231_def.xml Edgar Link unprocessable
nktr-20141231_lab.xml Edgar Link unprocessable
nktr-20141231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending